{"id":5747,"date":"2024-07-10T22:18:35","date_gmt":"2024-07-10T15:18:35","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=5747"},"modified":"2024-07-10T22:18:35","modified_gmt":"2024-07-10T15:18:35","slug":"eligo-publishes-in-nature-a-landmark-study-that-unlocks-genome-editing-of-bacteria-in-the-gut","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=5747","title":{"rendered":"Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut"},"content":{"rendered":"<p><span class=\"xn-location\">PARIS<\/span>, <span class=\"xn-chron\">July 10, 2024<\/span> \/PRNewswire\/ &#8212; For the first time, a team of scientists at\u00a0Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. This work provides scientists with a novel strategy to better understand how genes from our microbiome drive disease, as well as creates new opportunities for the development of innovative therapies. (Read the study <a href=\"https:\/\/www.nature.com\/articles\/s41586-024-07681-w\" target=\"_blank\" rel=\"noopener\">here\u00a0<\/a>\/\u00a0the\u00a0full\u00a0press\u00a0release <a href=\"https:\/\/eligo.bio\/eligo-nature-publication\/\" target=\"_blank\" rel=\"noopener\">here<\/a>).<\/p>\n<div>   <a href=\"https:\/\/mma.prnasia.com\/media2\/2458289\/Eligo_Bioscience_Artwork_Credit.jpg?p=medium600\" target=\"_blank\" rel=\"noopener\"><\/a>   <br \/>   <span>Eligo Publishes a Landmark Study in Nature That Unlocks Genome Editing of Bacteria in the Gut &#8211; Artwork Credit for the image: Radhika Patnala Sci-Illustrate<\/span>  <\/div>\n<p>The microbiome, composed of billions of bacteria, is essential to our health. However, we are discovering that bacterial genes are implicated in a growing number of diseases: from bacterial peptides that trigger\u00a0autoimmune diseases to virulence factors that contribute to inflammation, tumor formation, and neurodegenerative diseases.<\/p>\n<p>&#8220;What Eligo has achieved shows that it&#8217;s now possible to make specific changes to the DNA of\u00a0bacteria in the gut, similar to how scientists have been editing human genes to investigate or\u00a0treat\u00a0genetic\u00a0disorders,&#8221;\u00a0said\u00a0David\u00a0Bikard, cofounder of Eligo\u00a0Bioscience\u00a0and\u00a0researcher\u00a0at\u00a0the\u00a0Institut Pasteur in <span class=\"xn-location\">Paris<\/span>.<\/p>\n<p>Eligo\u00a0demonstrated\u00a0the\u00a0ability\u00a0to\u00a0engineer\u00a0a\u00a0bacteriophage-derived\u00a0capsid containing\u00a0a\u00a0synthetic\u00a0DNA payload encoding a base-editor system. After oral administration to mice, the capsid\u00a0delivered the payload with extreme efficiency to target bacterial populations residing among the\u00a0hundreds of bacterial species in the mouse gut. Remarkably, the system could precisely\u00a0inactivate antibiotic\u00a0resistance\u00a0genes\u00a0by\u00a0creating single-base\u00a0pair\u00a0mutations in\u00a0the\u00a0corresponding genes. When targeting E. coli strains, the technology modified the target gene in over 90% of the bacteria, reaching up to 99.7% in some cases.<\/p>\n<p>Jesus\u00a0Fernandez,\u00a0Eligo\u00a0VP\u00a0of\u00a0Technology\u00a0and\u00a0a\u00a0senior author\u00a0of\u00a0the\u00a0study,\u00a0highlights\u00a0how\u00a0&#8220;this achievement is the culmination of eight years of work by the team at Eligo Bioscience and\u00a0represents a paradigm shift in microbiome research. This leap forward provides Eligo with a unique edge within the industry to develop novel genetic medicines, as well as to find novel targets. We finally now have a tool to interrogate the role of specific bacterial genes in health and disease.&#8221;<\/p>\n<p>About Eligo Bioscience<\/p>\n<p>Eligo\u00a0is\u00a0pioneering\u00a0in\u00a0microbiome\u00a0in-vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in\u00a0immuno-inflammation, oncology, and infectious diseases.<\/p>\n<p>For\u00a0more\u00a0information:\u00a0<a href=\"https:\/\/eligo.bio\/\" target=\"_blank\" rel=\"noopener\">https:\/\/eligo.bio\/<\/a><\/p>\n<p>Contact: DUPORTET Xavier; <a href=\"mailto:xavier.duportet@eligo-bioscience.com\" target=\"_blank\" rel=\"noopener\">xavier.duportet@eligo-bioscience.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"xn-location\">PARIS<\/span>, <span class=\"xn-chron\">July 10, 2024<\/span> \/PRNewswire\/ &#8212; For the first time, a team of scientists at\u00a0Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. This work provides scientists with a novel strategy to better understand how genes from our microbiome drive disease, as well as creates new opportunities for the development of innovative therapies. (Read the study <a href=\"https:\/\/www.nature.com\/articles\/s41586-024-07681-w\" target=\"_blank\" rel=\"noopener\">here\u00a0<\/a>\/\u00a0the\u00a0full\u00a0press\u00a0release <a href=\"https:\/\/eligo.bio\/eligo-nature-publication\/\" target=\"_blank\" rel=\"noopener\">here<\/a>).<\/p>\n<div>   <a href=\"https:\/\/mma.prnasia.com\/media2\/2458289\/Eligo_Bioscience_Artwork_Credit.jpg?p=medium600\" target=\"_blank\" rel=\"noopener\"><\/a>   <br \/>   <span>Eligo Publishes a Landmark Study in Nature That Unlocks Genome Editing of Bacteria in the Gut &#8211; Artwork Credit for the image: Radhika Patnala Sci-Illustrate<\/span>  <\/div>\n<p>The microbiome, composed of billions of bacteria, is essential to our health. However, we are discovering that bacterial genes are implicated in a growing number of diseases: from bacterial peptides that trigger\u00a0autoimmune diseases to virulence factors that contribute to inflammation, tumor formation, and neurodegenerative diseases.<\/p>\n<p>&#8220;What Eligo has achieved shows that it&#8217;s now possible to make specific changes to the DNA of\u00a0bacteria in the gut, similar to how scientists have been editing human genes to investigate or\u00a0treat\u00a0genetic\u00a0disorders,&#8221;\u00a0said\u00a0David\u00a0Bikard, cofounder of Eligo\u00a0Bioscience\u00a0and\u00a0researcher\u00a0at\u00a0the\u00a0Institut Pasteur in <span class=\"xn-location\">Paris<\/span>.<\/p>\n<p>Eligo\u00a0demonstrated\u00a0the\u00a0ability\u00a0to\u00a0engineer\u00a0a\u00a0bacteriophage-derived\u00a0capsid containing\u00a0a\u00a0synthetic\u00a0DNA payload encoding a base-editor system. After oral administration to mice, the capsid\u00a0delivered the payload with extreme efficiency to target bacterial populations residing among the\u00a0hundreds of bacterial species in the mouse gut. Remarkably, the system could precisely\u00a0inactivate antibiotic\u00a0resistance\u00a0genes\u00a0by\u00a0creating single-base\u00a0pair\u00a0mutations in\u00a0the\u00a0corresponding genes. When targeting E. coli strains, the technology modified the target gene in over 90% of the bacteria, reaching up to 99.7% in some cases.<\/p>\n<p>Jesus\u00a0Fernandez,\u00a0Eligo\u00a0VP\u00a0of\u00a0Technology\u00a0and\u00a0a\u00a0senior author\u00a0of\u00a0the\u00a0study,\u00a0highlights\u00a0how\u00a0&#8220;this achievement is the culmination of eight years of work by the team at Eligo Bioscience and\u00a0represents a paradigm shift in microbiome research. This leap forward provides Eligo with a unique edge within the industry to develop novel genetic medicines, as well as to find novel targets. We finally now have a tool to interrogate the role of specific bacterial genes in health and disease.&#8221;<\/p>\n<p>About Eligo Bioscience<\/p>\n<p>Eligo\u00a0is\u00a0pioneering\u00a0in\u00a0microbiome\u00a0in-vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in\u00a0immuno-inflammation, oncology, and infectious diseases.<\/p>\n<p>For\u00a0more\u00a0information:\u00a0<a href=\"https:\/\/eligo.bio\/\" target=\"_blank\" rel=\"noopener\">https:\/\/eligo.bio\/<\/a><\/p>\n<p>Contact: DUPORTET Xavier; <a href=\"mailto:xavier.duportet@eligo-bioscience.com\" target=\"_blank\" rel=\"noopener\">xavier.duportet@eligo-bioscience.com<\/a><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-5747","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/5747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5747"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/5747\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}